

## §5.201

*et seq.*), as amended, and the National Childhood Vaccine Injury Act of 1986 (42 U.S.C. 300aa-1 note), as amended hereafter, as follows:

(1) Section 2125 of the PHS Act (42 U.S.C. 300aa-25)—Recording and reporting of information.

(2) Section 2127 of the PHS Act (42 U.S.C. 300aa-27)—Mandate for safer childhood vaccines.

(3) Section 2128 of the PHS Act (42 U.S.C. 300aa-28)—Manufacturer record-keeping and reporting.

(4) Section 312 of the National Childhood Vaccine Injury Act of 1986—Related studies (42 U.S.C. 300aa-1 note), except that the authority to provide for notice and opportunity for public hearing on the review of vaccines and related illnesses and conditions under sections 312(a) and (d) of the National Childhood Vaccine Injury Act of 1986 is not redelegated by the Commissioner.

(5) Section 313 of the National Childhood Vaccine Injury Act of 1986—Study of other vaccine risks (42 U.S.C. 300aa-1 note), except that the authority to provide for notice and opportunity for public hearing on the establishment of guidelines regarding the risks to children of certain vaccines under section 313(a)(1)(B) and (b) of the National Childhood Vaccine Injury Act of 1986 is not redelegated by the Commissioner.

(6) Section 314 of the National Childhood Vaccine Injury Act of 1986—Review of warnings, use instructions, and precautionary information (42 U.S.C. 300aa-1 note).

(b) These officials may not further redelegate these authorities.

### **§5.201 Redelegation of the Center for Biologics Evaluation and Research Director's program authorities.**

(a) The following officials are authorized to perform all the functions of the Director, Center for Biologics Evaluation and Research (CBER) with regard to program authorities for their respective areas:

(1) Deputy Directors, CBER.

(2) Associate Directors, CBER.

(3) Office Directors, CBER.

(4) Division Directors, CBER.

(b) These officials may not further redelegate these authorities.

## 21 CFR Ch. I (4-1-03 Edition)

### **§5.202 Issuance of notices of opportunity for a hearing on proposals for denial of approval of applications for licenses, suspension of licenses, or revocation of licenses and certain notices of revocation of licenses.**

(a) The Director and Deputy Directors, Center for Biologics Evaluation and Research are authorized to issue:

(1) Notices of opportunity for a hearing on proposals to deny approval or filing of applications for biologics licenses under §601.4(b) of this chapter.

(2) Notices of opportunity for a hearing on proposals to revoke biologics licenses under §601.5(b) of this chapter.

(3) Notices of revocation, at the manufacturer's request, of biologics licenses under §§601.5(a) and 601.8 of this chapter.

(4) Notices of revocation when the manufacturer has waived the opportunity for hearing under §601.7(a) of this chapter.

(5) Notice of biologics license suspensions under §601.6 of this chapter.

(b) These officials may not further redelegate these authorities.

### **§5.203 Issuance and revocation of licenses for the propagation or manufacture and preparation of biological products.**

(a) The following officials are authorized to issue licenses under section 351 of the PHS Act (42 U.S.C. 262) for the propagation or manufacture and preparation of biological products as specified in the PHS Act, and to revoke such licenses at the manufacturer's request:

(1) The Director and Deputy Directors, Center for Biologics Evaluation and Research (CBER).

(2) Directors and Deputy Directors, Office of Blood Research and Review, Office of Vaccines Research and Review, Office of Therapeutics Research and Review, and Office of Compliance and Biologics Quality, CBER.

(b) These officials may not further redelegate this authority.

### **§5.204 Notification of release for distribution of biological products.**

(a) The following officials are authorized to issue written notices of release for distribution of licensed biological products under subchapter F (parts 600 through 680.31) of this chapter: